JP2017500289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500289A5 JP2017500289A5 JP2016531049A JP2016531049A JP2017500289A5 JP 2017500289 A5 JP2017500289 A5 JP 2017500289A5 JP 2016531049 A JP2016531049 A JP 2016531049A JP 2016531049 A JP2016531049 A JP 2016531049A JP 2017500289 A5 JP2017500289 A5 JP 2017500289A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- amino
- acetyl
- hpyy
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 58
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 33
- -1 PYY compound Chemical class 0.000 claims 32
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 30
- 101100289894 Caenorhabditis elegans lys-7 gene Proteins 0.000 claims 15
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- VNWXCGKMEWXYBP-YFKPBYRVSA-N (3s)-3-amino-6-(diaminomethylideneamino)hexanoic acid Chemical compound OC(=O)C[C@@H](N)CCCNC(N)=N VNWXCGKMEWXYBP-YFKPBYRVSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 0 *C([C@@](CCCCNC(*OCCOCCNC(COCCOCCNC(CC[C@@](C(O)=O)NC(CC[C@@](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)N*)=O Chemical compound *C([C@@](CCCCNC(*OCCOCCNC(COCCOCCNC(CC[C@@](C(O)=O)NC(CC[C@@](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)N*)=O 0.000 description 1
- XCWVXTGEFYFFQZ-FHBSJOOWSA-N CC1(CC(N[C@@H](Cc(cc2)ccc2O)C(N)=O)=O)C(CCNC(N)N)C1 Chemical compound CC1(CC(N[C@@H](Cc(cc2)ccc2O)C(N)=O)=O)C(CCNC(N)N)C1 XCWVXTGEFYFFQZ-FHBSJOOWSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13193080 | 2013-11-15 | ||
| EP13193080.2 | 2013-11-15 | ||
| US201361906022P | 2013-11-19 | 2013-11-19 | |
| US61/906,022 | 2013-11-19 | ||
| PCT/EP2014/074477 WO2015071356A1 (en) | 2013-11-15 | 2014-11-13 | Hpyy(1 -36) having a beta-homoarginine substitution at position 35 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500289A JP2017500289A (ja) | 2017-01-05 |
| JP2017500289A5 true JP2017500289A5 (enExample) | 2017-12-07 |
| JP6629198B2 JP6629198B2 (ja) | 2020-01-15 |
Family
ID=49582656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531049A Active JP6629198B2 (ja) | 2013-11-15 | 2014-11-13 | ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６） |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10583172B2 (enExample) |
| EP (1) | EP3068795B1 (enExample) |
| JP (1) | JP6629198B2 (enExample) |
| CN (1) | CN105764919B (enExample) |
| WO (1) | WO2015071356A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS56998B1 (sr) | 2010-12-16 | 2018-05-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
| CN104203266B (zh) | 2012-03-22 | 2017-12-26 | 诺和诺德股份有限公司 | Glp‑1肽组合物及其制备 |
| BR112015026325A2 (pt) | 2013-05-02 | 2017-07-25 | Novo Nordisk As | dosagem oral de compostos glp-1 |
| CA2929672A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| TWI694082B (zh) * | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
| JP7076442B2 (ja) | 2016-11-07 | 2022-05-27 | ノヴォ ノルディスク アー／エス | Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用 |
| WO2019149880A1 (en) | 2018-02-02 | 2019-08-08 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| GB2573145A (en) * | 2018-04-26 | 2019-10-30 | Univ Ulster | Peptides for metabolic disease |
| GB201908426D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Appetite suppressing compounds |
| JP2022543826A (ja) * | 2019-08-07 | 2022-10-14 | ノヴォ ノルディスク アー／エス | Ｐｙｙ化合物とｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物 |
| MX2022005661A (es) * | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
| EP4281464A4 (en) | 2021-01-20 | 2025-01-01 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| AU2022347024A1 (en) | 2021-09-15 | 2024-05-02 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ265452A (en) | 1993-03-29 | 1997-09-22 | Univ Cincinnati | Analogues of peptide yy, dimers and pharmaceutical compositions |
| US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
| WO1998020885A1 (en) | 1996-11-13 | 1998-05-22 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
| EP0908515A3 (en) | 1997-09-16 | 2000-04-26 | Smithkline Beecham Plc | Pancreatic polypeptide |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| CN1311773A (zh) | 1998-06-08 | 2001-09-05 | 先灵公司 | 神经肽y5受体拮抗剂 |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| EP2123293A3 (en) | 2000-12-14 | 2010-09-08 | Amylin Pharmaceuticals, Inc. | Peptide YY and petide YY agonists for treatment of metabolic disorders |
| US6589938B2 (en) | 2001-06-29 | 2003-07-08 | National University Of Singapore | Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| NZ532427A (en) | 2001-09-24 | 2008-07-31 | Imp Innovations Ltd | Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y) |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| EP2277527A3 (en) | 2003-01-17 | 2011-08-31 | Ipsen Pharma | Peptide YY analogs |
| US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| WO2005027978A2 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| EP1667724A2 (en) | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CN1893980A (zh) | 2003-12-18 | 2007-01-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp－1类似物 |
| RU2378285C2 (ru) | 2004-02-11 | 2010-01-10 | Амилин Фармасьютикалз, Инк. | Гибридные полипептиды с селектируемыми свойствами |
| EP2335716A3 (en) | 2004-02-11 | 2011-10-19 | Amylin Pharmaceuticals Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| MXPA06010345A (es) | 2004-03-17 | 2007-06-19 | 7Tm Pharma As | Agonistas de receptor selectivo de y4 para intervenciones terapeuticas. |
| EP2272524A3 (en) | 2004-03-17 | 2011-02-02 | 7TM Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
| CN1933848A (zh) | 2004-03-17 | 2007-03-21 | 7Tm制药联合股份有限公司 | 用于治疗性干预的y2选择性受体激动剂 |
| CA2560166A1 (en) | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y2/y4 selective receptor agonists for therapeutic interventions |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| WO2006005667A2 (en) | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| US7994119B2 (en) | 2004-07-19 | 2011-08-09 | University Of Cincinnati | Compounds for control of appetite |
| WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
| US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| KR20080033392A (ko) | 2005-07-11 | 2008-04-16 | 나스텍 파마수티컬 컴퍼니 인코포레이티드 | 펩타이드 ｙｙ의 향상된 점막 전달을 위한 제형들 |
| US20090203581A1 (en) | 2005-07-18 | 2009-08-13 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| WO2007038942A1 (en) | 2005-09-21 | 2007-04-12 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
| CA2623094A1 (en) | 2005-09-21 | 2007-04-12 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
| EP1962959B1 (en) | 2005-12-07 | 2012-03-14 | F. Hoffmann-La Roche AG | Neuropeptide-2 receptor-agonists |
| US20100029903A1 (en) | 2005-12-14 | 2010-02-04 | Novo Nordisk A/S | Polypeptide Protracting Tags |
| US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
| WO2007109354A2 (en) | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| US20090099074A1 (en) | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
| EP2101822A2 (en) | 2007-01-18 | 2009-09-23 | Novo Nordisk A/S | Use of peptides in combination with surgical intervention for the treatment of obesity |
| WO2008087186A2 (en) | 2007-01-18 | 2008-07-24 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| GB0708226D0 (en) | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
| US20100279930A1 (en) | 2007-07-09 | 2010-11-04 | Stephen Robert Bloom | Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour |
| CN101842109B (zh) | 2007-09-05 | 2014-01-29 | 诺沃-诺迪斯克有限公司 | 用a-b-c-d-衍生的肽和它们的治疗用途 |
| WO2009043477A2 (en) | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent |
| US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| KR20110017874A (ko) * | 2008-05-16 | 2011-02-22 | 노보 노르디스크 에이/에스 | 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제 |
| US8299023B2 (en) | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
| GB0817067D0 (en) | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
| KR20110097807A (ko) | 2008-11-05 | 2011-08-31 | 에프. 호프만-라 로슈 아게 | 뉴로펩티드-2-수용체(ｙ-2ｒ) 작용제 및 이의 용도 |
| EP2398492A4 (en) | 2009-02-20 | 2013-07-17 | Ipsen Pharma Sas | CYTOTOXIC CONJUGATES HAVING NEUROPEPTIDE Y RECEPTOR BINDING COMPOUND |
| CN102573888A (zh) * | 2009-09-18 | 2012-07-11 | 诺和诺德公司 | 长效y2 受体激动剂 |
| EP2488195A2 (en) | 2009-10-13 | 2012-08-22 | F. Hoffmann-La Roche AG | Neuropeptide-2 receptor (y-2r) agonists |
| US20130096055A1 (en) | 2009-11-13 | 2013-04-18 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| WO2011131646A1 (en) | 2010-04-20 | 2011-10-27 | Novo Nordisk A/S | Long-acting gastrin derivatives |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| EP2855517A1 (en) | 2012-05-29 | 2015-04-08 | Novo Nordisk A/S | Pancreatic polypeptide compounds and use |
| CN105263957A (zh) | 2013-05-02 | 2016-01-20 | 葛兰素史克知识产权开发有限公司 | 治疗肽 |
| CA2929672A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| TWI694082B (zh) | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
-
2014
- 2014-11-13 WO PCT/EP2014/074477 patent/WO2015071356A1/en not_active Ceased
- 2014-11-13 US US15/036,509 patent/US10583172B2/en active Active
- 2014-11-13 JP JP2016531049A patent/JP6629198B2/ja active Active
- 2014-11-13 CN CN201480062212.0A patent/CN105764919B/zh active Active
- 2014-11-13 EP EP14802834.3A patent/EP3068795B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500289A5 (enExample) | ||
| JP2017505284A5 (enExample) | ||
| RU2017145348A (ru) | Селективные соединения пептида yy и их применения | |
| JP2018522843A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2013533227A5 (enExample) | ||
| JP2015517459A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
| JP2016006096A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2015513544A5 (enExample) | ||
| WO2011086093A3 (en) | Pharmaceutical compositions for oral administration of insulin peptides | |
| EP4410833A3 (en) | Compositions and methods for treating fatty tissue buildup | |
| WO2015128403A3 (en) | An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| JP2013522326A5 (enExample) | ||
| NZ600477A (en) | Insulin analogues with chlorinated amino acids | |
| JP2011046708A5 (enExample) | ||
| JP2010518061A5 (enExample) | ||
| JP2015514781A5 (enExample) | ||
| JP2017522300A5 (enExample) | ||
| WO2014071405A3 (en) | Long-acting single-chain insulin analogues | |
| JP2015516419A5 (enExample) |